$3.71
▼ $-0.06
(-1.59%)
Vol 91K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$105.2M
ROE
-337.9%
Margin
-67.1%
D/E
938.99
Beta
1.76
52W
$3–$14
Wall Street Consensus
12 analysts · Apr 20263
Strong Buy
6
Buy
3
Hold
0
Sell
0
Strong Sell
75.0%
Buy Rating
Price Chart
Similar Stocks
SPRB
Spruce Biosciences, Inc
$93.2M
COYA
Coya Therapeutics Inc
$121.4M
QTTB
Q32 Bio Inc
$40.9M
PYXS
Pyxis Oncology Inc
$71.6M
MCRB
Seres Therapeutics Inc
P/E 25.0
$134.6M
GOSS
Gossamer Bio Inc
$717.5M
HURA
TuHURA Biosciences Inc
$45.9M
ANIX
Anixa Biosciences Inc
$102.7M
ATYR
aTyr Pharma Inc
$76.7M
FBIO
Fortress Biotech Inc
P/E 28.5
$113.6M
Earnings
Beat rate: 0.0%
Next Report
May 06, 2026
EPS Estimate: $-0.29
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.29 | — | — |
| Dec 2025 | $-0.34 | $-0.38 | $-0.04 |
| Sep 2025 | $-0.29 | $-0.46 | $-0.17 |
| Jun 2025 | $-0.25 | $-0.38 | $-0.13 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -337.9% | -337.9% | -337.9% | -337.9% | -337.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -53.9% | -68.9% | -68.9% | -68.9% | -67.1% | -67.1% |
| Gross Margin | 82.4% | 392.2% | 392.2% | 392.2% | 84.8% | 84.8% |
| D/E Ratio | — | 938.99 | 938.99 | 938.99 | 938.99 | 938.99 |
| Current Ratio | 0.58 | 0.58 | 0.58 | 0.58 | 0.67 | 0.67 |
Key Ratios
ROA (TTM)
-71.6%
P/S (TTM)
1.45
P/B
67.1
EPS (TTM)
$-1.81
CF/Share
$-1.31
Rev Growth 3Y
+66.4%
52W High
$14.16
52W Low
$3.25
$3.25
52-Week Range
$14.16
How does RCEL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
RCEL valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.5
▼
89%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
67.1
▲
2628%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
RCEL profitability vs Biotechnology peers
ROE
-337.9%
▼
402%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-67.1%
▲
77%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
84.8%
▲
8%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-71.6%
▼
53%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
RCEL financial health vs Biotechnology peers
D/E ratio
939.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
0.7
▼
85%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.8
▲
81%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
RCEL fundamentals radar
RCEL
Peer median
Industry
RCEL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio